The inflammatory response caused by cancer-initiating mutations during cancer development has been demonstrated to be non-resolved. Once the inflammatory tumor microenvironment (TME) is established, inflammatory factors could promote cell proliferation, prolong cell survival and result in immunosuppressive TME.
Due to the close relationship between inflammation and tumor, potential strategies to modulate inflammation might exhibit antitumor activity. For example, non-steroidal anti-inflammatory drugs (NSAIDs) had been investigated in numerous studies indicating that NSAIDs significantly reduce the risk of development of multiple types of cancer, including breast cancer, colorectal cancer (CRC), and hepatocellular carcinoma (HCC). However, most of the agents targeting non-resolving inflammation or cancer lack efficient therapeutic effects with severe side effects. To address the issue, innovative agents or approaches are urgently needed to be investigated. Recently, novel chemistry agents, antibody, exosome and biomimetic drugs combined with the advanced delivery system have shown huge potential for inflammation intervention or cancer therapy.
This Research Topic aims at presenting the trend and recent advances on innovative therapeutic strategies or drug delivery systems targeting the inflammatory tumor microenvironment. We welcome basic research with a focus on drug investigation about tumor-associated inflammation therapy.
We welcome Original Articles, Reviews and Mini Reviews in the subtopics of interest, which include, but are not limited to the subtopics below:
• Identification of new mechanisms and signaling pathways involving in tumor-associated inflammation
• New targets for Inflammation intervention in cancer therapy
• Novel therapeutic approaches to treat inflammatory caused tumor progression
• Innovative drug formations (such as Nano drug or RNA drug) for Inflammation in cancer diagnosis and treatment
• Targeted delivery systems for the inflammatory tumor microenvironment
The inflammatory response caused by cancer-initiating mutations during cancer development has been demonstrated to be non-resolved. Once the inflammatory tumor microenvironment (TME) is established, inflammatory factors could promote cell proliferation, prolong cell survival and result in immunosuppressive TME.
Due to the close relationship between inflammation and tumor, potential strategies to modulate inflammation might exhibit antitumor activity. For example, non-steroidal anti-inflammatory drugs (NSAIDs) had been investigated in numerous studies indicating that NSAIDs significantly reduce the risk of development of multiple types of cancer, including breast cancer, colorectal cancer (CRC), and hepatocellular carcinoma (HCC). However, most of the agents targeting non-resolving inflammation or cancer lack efficient therapeutic effects with severe side effects. To address the issue, innovative agents or approaches are urgently needed to be investigated. Recently, novel chemistry agents, antibody, exosome and biomimetic drugs combined with the advanced delivery system have shown huge potential for inflammation intervention or cancer therapy.
This Research Topic aims at presenting the trend and recent advances on innovative therapeutic strategies or drug delivery systems targeting the inflammatory tumor microenvironment. We welcome basic research with a focus on drug investigation about tumor-associated inflammation therapy.
We welcome Original Articles, Reviews and Mini Reviews in the subtopics of interest, which include, but are not limited to the subtopics below:
• Identification of new mechanisms and signaling pathways involving in tumor-associated inflammation
• New targets for Inflammation intervention in cancer therapy
• Novel therapeutic approaches to treat inflammatory caused tumor progression
• Innovative drug formations (such as Nano drug or RNA drug) for Inflammation in cancer diagnosis and treatment
• Targeted delivery systems for the inflammatory tumor microenvironment
